Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody

References

• Chuntharapai A, Lee J, Hébert CA, Kim KJ. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol. 1994;153:5682.
   PubMed Web of Science ®Google Scholar
• Park SH, Das BB, Casagrande F, Tian Y, Nothnagel HJ, Chu M, Kiefer H, Maier K, De Angelis AA, Marassi FM, et al. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature. 2012;491(7426):779–15. doi:https://doi.org/10.1038/nature11580.
   PubMed Web of Science ®Google Scholar
• Gangur V, Birmingham NP, Thanesvorakul S. Chemokines in health and disease. Vet Immunol Immunopathol. 2002;86:127–36. doi:https://doi.org/10.1016/S0165-2427(02)00018-1.
   PubMed Web of Science ®Google Scholar
• Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol Rev. 2000;52:145.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM, et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer. 2009;125(5):1027–37. doi:https://doi.org/10.1002/ijc.24383.
   PubMed Web of Science ®Google Scholar
• Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem. 1996;271:20545–50. doi:https://doi.org/10.1074/jbc.271.34.20545.
   PubMed Web of Science ®Google Scholar
• Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 2017;7:1543–88. doi:https://doi.org/10.7150/thno.15625.
   PubMed Web of Science ®Google Scholar
• Acosta JC, Gil J. A role for CXCR2 in senescence, but what about in cancer? Cancer Res. 2009;69:2167–70. doi:https://doi.org/10.1158/0008-5472.CAN-08-3772.
   PubMed Web of Science ®Google Scholar
• Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21. doi:https://doi.org/10.1056/NEJMra052723.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, Chen Y, Han X, Wu K. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 2016;31:61–71. doi:https://doi.org/10.1016/j.cytogfr.2016.08.002.
   PubMed Web of Science ®Google Scholar
• Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735–41. doi:https://doi.org/10.1158/1078-0432.CCR-07-4843.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Borghi A, Wallach D, Cugno M. A comprehensive review of neutrophilic diseases. Clin Rev Allergy Immunol. 2018;54(1):114–30. doi:https://doi.org/10.1007/s12016-017-8621-8.
   PubMed Web of Science ®Google Scholar
• Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011;72(2):282–93. doi:https://doi.org/10.1111/j.1365-2125.2011.03968.x.
   PubMed Web of Science ®Google Scholar
• Austin RP, Bennion C, Bonnert RV, Cheema L, Cook AR, Cox RJ, Ebden MR, Gaw A, Grime K, Meghani P. Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists. Bioorg Med Chem Lett. 2015;25(7):1616–20. doi:https://doi.org/10.1016/j.bmcl.2015.01.067.
   PubMed Web of Science ®Google Scholar
• Busch-Petersen J, Carpenter DC, Burman M, Foley J, Hunsberger GE, Kilian DJ, Salmon M, Mayer RJ, Yonchuk JG, Tal-Singer R, et al. Danirixin: a reversible and selective antagonist of the CXC Chemokine Receptor 2. J Pharmacol Exp Ther. 2017;362(2):338–46. doi:https://doi.org/10.1124/jpet.117.240705.
   PubMed Web of Science ®Google Scholar
• Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015;353(2):340–50. doi:https://doi.org/10.1124/jpet.114.221358.
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O’Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–103. doi:https://doi.org/10.1111/j.1365-2222.2012.04014.x.
   PubMed Web of Science ®Google Scholar
• Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, et al. Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-Cell immunotherapy in head and neck cancer models. Clin Cancer Res. 2020;26(6):1420–31. doi:https://doi.org/10.1158/1078-0432.CCR-19-2625.
   PubMed Web of Science ®Google Scholar
• Schott AF, Goldstein LJ, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, Perez RP, Kato G, Wicha M. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer. Clin Cancer Res. 2017;23:5358–65. doi:https://doi.org/10.1158/1078-0432.CCR-16-2748.
   PubMed Web of Science ®Google Scholar
• Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004;101(32):11791–96. doi:https://doi.org/10.1073/pnas.0402090101.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, McCanna S, Butler B, Ruffini PA, Liu Y, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Res. 2020;22(1):4. doi:https://doi.org/10.1186/s13058-019-1243-8.
   PubMed Web of Science ®Google Scholar
• Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543(7647):728–32. doi:https://doi.org/10.1038/nature21676.
   PubMed Web of Science ®Google Scholar
• Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot EPJ, Hudson D, Baadsgaard O, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol (Baltimore, Md: 1950). 2008;181:669–79. doi:https://doi.org/10.4049/jimmunol.181.1.669.
   PubMed Web of Science ®Google Scholar
• Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol. 1999;66:401–10. doi:https://doi.org/10.1002/jlb.66.3.401.
   PubMed Web of Science ®Google Scholar
• Bangsgaard N, Houtkamp M, Schuurhuis DH, Parren PW, Baadsgaard O, Niessen HW, Skov L. Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. PLoS One. 2012;7(6):e39706. doi:https://doi.org/10.1371/journal.pone.0039706.
   PubMed Web of Science ®Google Scholar
• Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, Karzai F, Marté JL, Strauss J, Gatti-Mays ME. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019;7(1):240. doi:https://doi.org/10.1186/s40425-019-0706-x.
   PubMed Web of Science ®Google Scholar
• Hidalgo A, Chilvers ER, Summers C, Koenderman L. The neutrophil life cycle. Trends Immunol. 2019;40(7):584–97. doi:https://doi.org/10.1016/j.it.2019.04.013.
   PubMed Web of Science ®Google Scholar
• Jo M, Jung ST. Engineering therapeutic antibodies targeting G-protein-coupled receptors. Exp Mol Med. 2016;48:e207. doi:https://doi.org/10.1038/emm.2015.105.
   PubMed Web of Science ®Google Scholar
• Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol. 2011;11:355–63. doi:https://doi.org/10.1038/nri2972.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Koch AE. Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. Nat Rev Rheumatol. 2016;12:5–13. doi:https://doi.org/10.1038/nrrheum.2015.157.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ma X-L, Wei Y-Q, Wei X-W. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochimica et Biophysica Acta (BBA) - Rev Cancer. 2019;1871:289–312. doi:https://doi.org/10.1016/j.bbcan.2019.01.005.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012;526:159–66. doi:https://doi.org/10.1016/j.abb.2012.03.021.
   PubMed Web of Science ®Google Scholar
• Ravindran A, Joseph PR, Rajarathnam K. Structural basis for differential binding of the interleukin-8 monomer and dimer to the CXCR1 N-domain: role of coupled interactions and dynamics. Biochemistry. 2009;48:8795–805. doi:https://doi.org/10.1021/bi901194p.
   PubMed Web of Science ®Google Scholar
• Lawrence MC, Colman PM. Shape complementarity at protein/protein interfaces. J Mol Biol. 1993;234:946–50. doi:https://doi.org/10.1006/jmbi.1993.1648.
   PubMed Web of Science ®Google Scholar
• Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, Brookes DH, Wilson L, Chen J, Liles K, et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci. 2018;27:112–28.
   PubMed Web of Science ®Google Scholar
• Eisenberg D, Schwarz E, Komaromy M, Wall R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J Mol Biol. 1984;179:125–42. doi:https://doi.org/10.1016/0022-2836(84)90309-7.
   PubMed Web of Science ®Google Scholar
• Kohler A, De Filippo K, Hasenberg M, van den Brandt C, Nye E, Hosking MP, Lane TE, Männ L, Ransohoff RM, Hauser AE, et al. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood. 2011;117:4349–57. doi:https://doi.org/10.1182/blood-2010-09-308387.
   PubMed Web of Science ®Google Scholar
• Angelini A, Miyabe Y, Newsted D, Kwan BH, Miyabe C, Kelly RL, Jamy MN, Luster AD, Wittrup KD. Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. Nat Commun. 2018;9(1):1461. doi:https://doi.org/10.1038/s41467-018-03687-x.
   PubMedGoogle Scholar
• Bostrom J, Yu S-F, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science. 2009;323(5921):1610. doi:https://doi.org/10.1126/science.1165480.
   PubMed Web of Science ®Google Scholar
• Lee CV, Koenig P, Fuh G. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions. mAbs. 2014;6(3):622–27. doi:https://doi.org/10.4161/mabs.28483.
   PubMed Web of Science ®Google Scholar
• Felix J, Savvides SN. Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures. Nat Rev Immunol. 2017;17:112–29. doi:https://doi.org/10.1038/nri.2016.134.
   PubMed Web of Science ®Google Scholar
• Prado GN, Suetomi K, Shumate D, Maxwell C, Ravindran A, Rajarathnam K, Navarro J. Chemokine signaling specificity: essential role for the N-terminal domain of chemokine receptors. Biochemistry. 2007;46(31):8961–68. doi:https://doi.org/10.1021/bi7004043.
   PubMed Web of Science ®Google Scholar
• Proudfoot AE, Bonvin P, Power CA. Targeting chemokines: pathogens can, why can’t we? Cytokine. 2015;74:259–67. doi:https://doi.org/10.1016/j.cyto.2015.02.011.
   PubMed Web of Science ®Google Scholar
• Comerford I, McColl SR. Mini-review series: focus on chemokines. Immunol Cell Biol. 2011;89:183–84. doi:https://doi.org/10.1038/icb.2010.164.
   PubMed Web of Science ®Google Scholar
• Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow C-K, Chow C-K, Barmettler B, Nelson J, Bina H. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50. doi:https://doi.org/10.2147/JIR.S100940.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27(8):767–71. doi:https://doi.org/10.1038/nbt.1553.
   PubMed Web of Science ®Google Scholar
• Chai Q, Shih J, Weldon C, Phan S, Jones BE. Development of a high-throughput solubility screening assay for use in antibody discovery. MAbs. 2019;11:747–56. doi:https://doi.org/10.1080/19420862.2019.1589851.
   PubMed Web of Science ®Google Scholar
• Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683–90. doi:https://doi.org/10.1111/1523-1747.ep12613748.
   PubMed Web of Science ®Google Scholar
• Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985;82:488–92. doi:https://doi.org/10.1073/pnas.82.2.488.
   PubMed Web of Science ®Google Scholar
• Leslie AGW, Powell HR. Processing diffraction data with mosflm. In: Read RJ, Sussman JL, editors. Evolving methods for macromolecular crystallography: the structural path to the understanding of the mechanism of action of CBRN agents. Dordrecht: Springer Netherlands; 2007. p. 41–51.
   Google Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67:235–42. doi:https://doi.org/10.1107/S0907444910045749.
   PubMed Web of Science ®Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–74. doi:https://doi.org/10.1107/S0021889807021206.
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–32. doi:https://doi.org/10.1107/S0907444904019158.
   PubMed Web of Science ®Google Scholar
• Bricogne G, Brandl M, Flensburg C, Keller P, Paciorek W, Roversi P, Sharff A, Smart OS, Vonrhein C, Womack TO. BUSTER version 2.11.5. Cambridge (UK): Global Phasing Ltd; 2011.
   Google Scholar